Livionex, recently announced a successful end-of-Phase 2 meeting with the FDA, supporting the advancement of C-KAD, a 2.6% EDTA ophthalmic solution, to a Phase 3 clinical study. In an interview with ...
Clinical visits by patients suffering ocular surface eye conditions more than doubled during times when ambient particulate ...
The Valeda ® Light Delivery System (LumiThera, Inc.) is the first ever FDA-authorized treatment for vision loss in dry AMD, the manufacturer reported. The technology was evaluated in the LIGHTSITE III ...
Researchers have demonstrated that inebilizumab reduced the risk of symptoms by 87 percent in patients with the rare affliction known as immunoglobulin G4-related disease (IgG4-RD).
Neurobiology, Neurodegeneration and Repair Laboratory, National Eye Institute, National Institutes of Health, Bethesda, United States This important study employed multiple orthogonal techniques and ...
A delay in the FDA decision for NT-501 could leave those with macular telangiectasia (MacTel) without any form of treatment ...
The study sheds light on how specific mutations may lead to the retinal disease retinitis pigmentosa. Importantly, these findings could also open the door to new diagnostic tests and treatments for a ...
Common ocular autoimmune diseases include thyroid eye disease, orbital inflammatory pseudotumor ... prevention, diagnosis, and treatment. This Research Topic aims to explore advancements in the ...
Hopkins researchers are further investigating 32-134D in wet AMD and diabetic eye disease, as well as other blinding diseases ...
4d
A new treatment that could prevent blindness in children with the CLN2 type Batten disease has been trialed by clinicians and ...
GlobalData on MSN5d
FDA delays priority review of Neurotech’s eye cell therapy implantThe US regulatory agency has pushed the PDUFA date by three months to 18 March 2025 to “allow for more time to review ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback